Pulmonary Drug Delivery Systems Market

Executive Summary

Pulmonary Drug Delivery Systems Market was valued at US $55.80 billion in 2021 and is projected to grow at 7.58% CAGR over the forecast period to reach US $86.49 billion by 2027. Pulmonary Drug Delivery Systems Market represented US $7.58 billion opportunity over 2019-2021 and estimated to create US $30.69 billion opportunity in 2027 over 2021.

Pulmonary Drug Delivery Systems from Consainsights analyses the Pulmonary Drug Delivery Systems Market in the Life Sciences industry over the forecast period to 2027.

Pulmonary Drug Delivery Systems research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Pulmonary Drug Delivery Systems segmentation includes Product, Application, Distribution Channel, Region and Geography.

Based on the Product, the Pulmonary Drug Delivery Systems analysis covers DRY POWDER INHALERS, METERED DOSE INHALERS, NEBULIZERS.

In Product segment, DRY POWDER INHALERS segment has highest cagr growth of 6.71%.

Based on the Application, the Pulmonary Drug Delivery Systems analysis covers ASTHMA, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, CYSTIC FIBROSIS, OTHERS.

In Application segment, ASTHMA segment has highest cagr growth of 6.71%.

Based on the Distribution Channel, the Pulmonary Drug Delivery Systems analysis covers RETAIL PHARMACIES, HOSPITAL PHARMACIES, E-COMMERCE.

In Distribution Channel segment, RETAIL PHARMACIES segment has highest cagr growth of 6.71%.

Based on the Region, the Pulmonary Drug Delivery Systems analysis covers EUROPE, ASIA-PACIFIC, LAMEA.

In Region segment, EUROPE segment has highest cagr growth of 6.71%.

Based on the region, the Pulmonary Drug Delivery Systems analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include ASTRAZENECA PLC., BOEHRINGER INGELHEIM GMBH, GLAXOSMITHKLINE PLC, NOVARTIS AG, KONINKLIJKE PHILIPS N.V., 3M COMPANY, ACTELION PHARMACEUTICALS LTD, CLEMENT CLARKE INTERNATIONAL., BRIGGS HEALTHCARE, AEROGEN and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Product

Introduction

In 2021, DRY POWDER INHALERS segment has the highest revenue of US $23.77 billion and is expected to grow at CAGR of 6.71% by 2027 DRY POWDER INHALERS segment has highest cagr growth of 6.71%.

DRY POWDER INHALERS

DRY POWDER INHALERS segment was valued at US $20.54 billion in 2019 and is projected to grow at 6.71% CAGR over the forecast period to reach US $36.85 billion by 2027. DRY POWDER INHALERS segment represented US $3.23 billion opportunity over 2019-2021 and estimated to create US $13.08 billion opportunity in 2027 over 2021.

METERED DOSE INHALERS

METERED DOSE INHALERS segment was valued at US $19.33 billion in 2019 and is projected to grow at 6.71% CAGR over the forecast period to reach US $34.68 billion by 2027. METERED DOSE INHALERS segment represented US $3.04 billion opportunity over 2019-2021 and estimated to create US $12.31 billion opportunity in 2027 over 2021.

NEBULIZERS

NEBULIZERS segment was valued at US $8.34 billion in 2019 and is projected to grow at 6.71% CAGR over the forecast period to reach US $14.96 billion by 2027. NEBULIZERS segment represented US $1.31 billion opportunity over 2019-2021 and estimated to create US $5.31 billion opportunity in 2027 over 2021.

Application

Introduction

In 2021, ASTHMA segment has the highest revenue of US $20.71 billion and is expected to grow at CAGR of 6.71% by 2027 ASTHMA segment has highest cagr growth of 6.71%.

ASTHMA

ASTHMA segment was valued at US $17.90 billion in 2019 and is projected to grow at 6.71% CAGR over the forecast period to reach US $32.10 billion by 2027. ASTHMA segment represented US $2.81 billion opportunity over 2019-2021 and estimated to create US $11.39 billion opportunity in 2027 over 2021.

CHRONIC OBSTRUCTIVE PULMONARY DISEASE

CHRONIC OBSTRUCTIVE PULMONARY DISEASE segment was valued at US $15.73 billion in 2019 and is projected to grow at 6.71% CAGR over the forecast period to reach US $28.22 billion by 2027. CHRONIC OBSTRUCTIVE PULMONARY DISEASE segment represented US $2.47 billion opportunity over 2019-2021 and estimated to create US $10.01 billion opportunity in 2027 over 2021.

CYSTIC FIBROSIS

CYSTIC FIBROSIS segment was valued at US $10.16 billion in 2019 and is projected to grow at 6.71% CAGR over the forecast period to reach US $18.23 billion by 2027. CYSTIC FIBROSIS segment represented US $1.60 billion opportunity over 2019-2021 and estimated to create US $6.47 billion opportunity in 2027 over 2021.

OTHERS

OTHERS segment was valued at US $4.42 billion in 2019 and is projected to grow at 6.71% CAGR over the forecast period to reach US $7.93 billion by 2027. OTHERS segment represented US $0.70 billion opportunity over 2019-2021 and estimated to create US $2.82 billion opportunity in 2027 over 2021.

Distribution Channel

Introduction

In 2021, RETAIL PHARMACIES segment has the highest revenue of US $26.65 billion and is expected to grow at CAGR of 6.71% by 2027 RETAIL PHARMACIES segment has highest cagr growth of 6.71%.

RETAIL PHARMACIES

RETAIL PHARMACIES segment was valued at US $23.03 billion in 2019 and is projected to grow at 6.71% CAGR over the forecast period to reach US $41.31 billion by 2027. RETAIL PHARMACIES segment represented US $3.62 billion opportunity over 2019-2021 and estimated to create US $14.66 billion opportunity in 2027 over 2021.

HOSPITAL PHARMACIES

HOSPITAL PHARMACIES segment was valued at US $19.86 billion in 2019 and is projected to grow at 6.71% CAGR over the forecast period to reach US $35.62 billion by 2027. HOSPITAL PHARMACIES segment represented US $3.12 billion opportunity over 2019-2021 and estimated to create US $12.64 billion opportunity in 2027 over 2021.

E-COMMERCE

E-COMMERCE segment was valued at US $5.33 billion in 2019 and is projected to grow at 6.71% CAGR over the forecast period to reach US $9.56 billion by 2027. E-COMMERCE segment represented US $0.84 billion opportunity over 2019-2021 and estimated to create US $3.39 billion opportunity in 2027 over 2021.

Region

Introduction

In 2021, EUROPE segment has the highest revenue of US $41.52 billion and is expected to grow at CAGR of 6.71% by 2027 EUROPE segment has highest cagr growth of 6.71%.

EUROPE

EUROPE segment was valued at US $35.88 billion in 2019 and is projected to grow at 6.71% CAGR over the forecast period to reach US $64.36 billion by 2027. EUROPE segment represented US $5.64 billion opportunity over 2019-2021 and estimated to create US $22.84 billion opportunity in 2027 over 2021.

ASIA-PACIFIC

ASIA-PACIFIC segment was valued at US $10.31 billion in 2019 and is projected to grow at 6.71% CAGR over the forecast period to reach US $18.49 billion by 2027. ASIA-PACIFIC segment represented US $1.62 billion opportunity over 2019-2021 and estimated to create US $6.56 billion opportunity in 2027 over 2021.

LAMEA

LAMEA segment was valued at US $2.03 billion in 2019 and is projected to grow at 6.71% CAGR over the forecast period to reach US $3.64 billion by 2027. LAMEA segment represented US $0.32 billion opportunity over 2019-2021 and estimated to create US $1.29 billion opportunity in 2027 over 2021.